Skip to main content
Erschienen in: World Journal of Urology 12/2020

17.02.2020 | Original Article

Adjuvant chemotherapy improves overall survival in patients with localized upper tract urothelial carcinoma harboring pathologic vascular invasion: a propensity score-matched analysis of multi-institutional cohort

verfasst von: Tomohisa Matsunaga, Kazumasa Komura, Takeshi Hashimoto, Ryu Muraoka, Naoya Satake, Takeshi Tsutsumi, Takuya Tsujino, Yuki Yoshikawa, Tomoaki Takai, Koichiro Minami, Kohei Taniguchi, Tomohito Tanaka, Hirofumi Uehara, Hajime Hirano, Hayahito Nomi, Naokazu Ibuki, Kiyoshi Takahara, Teruo Inamoto, Yoshio Ohno, Haruhito Azuma

Erschienen in: World Journal of Urology | Ausgabe 12/2020

Einloggen, um Zugang zu erhalten

Abstract

Objective

Whether adjuvant chemotherapy (AC) for patients with upper tract urothelial carcinoma (UTUC) offers survival benefit is still controversial. To explore the impact of AC on overall survival (OS) of cN0M0 UTUC patients, we conducted a propensity score-matched analysis using the regression model, including pathologic features such as lymphatic and vascular invasion.

Methods

A multi-institutional cohort of 413 UTUC patient record was used. Propensity score matching was performed to reduce bias by potential confounding factors for survival, including pathologic features from the specimen of radical nephroureterectomy (RNU),

Results

Ninety-eight patients were identified as pair-matched groups (49 patients in RNU and 49 patients in RNU + AC). Kaplan–Meier curves demonstrated that a 5-year OS rate of 72.7% for patients treated with RNU + AC was significantly higher than 51.6% for those treated with RNU (p = 0.0156). On multivariate analysis, pathologic vascular invasion (HR 3.41, 95% CI 1.24–10.66, p = 0.0166) and administration of AC (HR 0.45, 95% CI 0.19–0.98, p = 0.0438) still remained as the significant predictors for OS. In patients with pathologic vascular invasion (51 of 98 patients), a significantly longer OS in RNU + AC groups was observed (median OS of 30 and 70 months in RNU and RNU + AC groups, respectively: p = 0.0432), whereas there was no significant difference in the OS between RNU (median OS: not reached) and RNU + AC (median OS: not reached) groups in patients without the invasion (p = 0.4549).

Conclusion

The result indicates a significant benefit for OS by the administration of AC, and pathologic vascular invasion in the specimen of RNU could help the patient selection to better predict the effect of AC.
Literatur
1.
Zurück zum Zitat Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7–30CrossRef Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7–30CrossRef
2.
Zurück zum Zitat Roupret M, Babjuk M, Comperat E et al (2018) European association of urology guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol 73(1):111–122CrossRef Roupret M, Babjuk M, Comperat E et al (2018) European association of urology guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol 73(1):111–122CrossRef
3.
Zurück zum Zitat Kim TS, Oh JH, Rhew HY (2013) The efficacy of adjuvant chemotherapy for locally advanced upper tract urothelial cell carcinoma. J Cancer 4(8):686–690CrossRef Kim TS, Oh JH, Rhew HY (2013) The efficacy of adjuvant chemotherapy for locally advanced upper tract urothelial cell carcinoma. J Cancer 4(8):686–690CrossRef
4.
Zurück zum Zitat Fujita K, Taneishi K, Inamoto T et al (2017) Adjuvant chemotherapy improves survival of patients with high-risk upper urinary tract urothelial carcinoma: a propensity score-matched analysis. BMC Urol 17(1):110 Fujita K, Taneishi K, Inamoto T et al (2017) Adjuvant chemotherapy improves survival of patients with high-risk upper urinary tract urothelial carcinoma: a propensity score-matched analysis. BMC Urol 17(1):110
5.
Zurück zum Zitat Nakagawa T, Komemushi Y, Kawai T et al (2017) Efficacy of post-nephroureterectomy cisplatin-based adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: a multi-institutional retrospective study. World J Urol 35(10):1569–1575CrossRef Nakagawa T, Komemushi Y, Kawai T et al (2017) Efficacy of post-nephroureterectomy cisplatin-based adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: a multi-institutional retrospective study. World J Urol 35(10):1569–1575CrossRef
6.
Zurück zum Zitat Fujita K, Inamoto T, Yamamoto Y et al (2015) Role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma and the prognostic significance of C-reactive protein: a multi-institutional, retrospective study. Int J Urol 22(11):1006–1012CrossRef Fujita K, Inamoto T, Yamamoto Y et al (2015) Role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma and the prognostic significance of C-reactive protein: a multi-institutional, retrospective study. Int J Urol 22(11):1006–1012CrossRef
7.
Zurück zum Zitat Gin GE, Ruel NH, Kardos SV et al (2017) Utilization of perioperative systemic chemotherapy in upper tract urothelial carcinoma. Urol Oncol 35(5):192–200CrossRef Gin GE, Ruel NH, Kardos SV et al (2017) Utilization of perioperative systemic chemotherapy in upper tract urothelial carcinoma. Urol Oncol 35(5):192–200CrossRef
8.
Zurück zum Zitat Hellenthal NJ, Shariat SF, Margulis V et al (2009) Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. J Urol 182(3):900–906CrossRef Hellenthal NJ, Shariat SF, Margulis V et al (2009) Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. J Urol 182(3):900–906CrossRef
9.
Zurück zum Zitat Kwak C, Lee SE, Jeong IG, Ku JH (2006) Adjuvant systemic chemotherapy in the treatment of patients with invasive transitional cell carcinoma of the upper urinary tract. Urology 68(1):53–57CrossRef Kwak C, Lee SE, Jeong IG, Ku JH (2006) Adjuvant systemic chemotherapy in the treatment of patients with invasive transitional cell carcinoma of the upper urinary tract. Urology 68(1):53–57CrossRef
10.
Zurück zum Zitat Yang X, Li P, Deng X et al (2017) Perioperative treatments for resected upper tract urothelial carcinoma: a network meta-analysis. Oncotarget 8(2):3568–3580CrossRef Yang X, Li P, Deng X et al (2017) Perioperative treatments for resected upper tract urothelial carcinoma: a network meta-analysis. Oncotarget 8(2):3568–3580CrossRef
11.
Zurück zum Zitat Seisen T, Krasnow RE, Bellmunt J et al (2017) Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally advanced and/or positive regional lymph node upper tract urothelial carcinoma. J Clin Oncol 35(8):852–860CrossRef Seisen T, Krasnow RE, Bellmunt J et al (2017) Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally advanced and/or positive regional lymph node upper tract urothelial carcinoma. J Clin Oncol 35(8):852–860CrossRef
12.
Zurück zum Zitat Necchi A, Lo Vullo S, Mariani L et al (2018) Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration. BJU Int 121(2):252–259CrossRef Necchi A, Lo Vullo S, Mariani L et al (2018) Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration. BJU Int 121(2):252–259CrossRef
13.
Zurück zum Zitat Song SH, Ye CH, Lee S et al (2019) Association between lymphovascular invasion and oncologic outcomes among upper urinary tract urothelial carcinoma patients who underwent radical nephroureterectomy. J Cancer Res Clin Oncol 145(11):2863–2870CrossRef Song SH, Ye CH, Lee S et al (2019) Association between lymphovascular invasion and oncologic outcomes among upper urinary tract urothelial carcinoma patients who underwent radical nephroureterectomy. J Cancer Res Clin Oncol 145(11):2863–2870CrossRef
14.
Zurück zum Zitat Novara G, Matsumoto K, Kassouf W et al (2010) Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study. Eur Urol 57(6):1064–1071CrossRef Novara G, Matsumoto K, Kassouf W et al (2010) Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study. Eur Urol 57(6):1064–1071CrossRef
15.
Zurück zum Zitat Kikuchi E, Margulis V, Karakiewicz PI et al (2009) Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. J Clin Oncol 27(4):612–618CrossRef Kikuchi E, Margulis V, Karakiewicz PI et al (2009) Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. J Clin Oncol 27(4):612–618CrossRef
16.
Zurück zum Zitat Birtle AJ, Chester JD, Jones RJ et al (2018) Results of POUT: A phase III randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC). J Clin Oncol 36(6_suppl):407–407 Birtle AJ, Chester JD, Jones RJ et al (2018) Results of POUT: A phase III randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC). J Clin Oncol 36(6_suppl):407–407
17.
Zurück zum Zitat World Medical A (2013) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310(20):2191–2194CrossRef World Medical A (2013) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310(20):2191–2194CrossRef
18.
Zurück zum Zitat Inamoto T, Matsuyama H, Ibuki N et al (2018) Risk stratification by means of biological age-related factors better predicts cancer-specific survival than chronological age in patients with upper tract urothelial carcinoma: a multi-institutional database study. Ther Adv Urol 10(12):403–410CrossRef Inamoto T, Matsuyama H, Ibuki N et al (2018) Risk stratification by means of biological age-related factors better predicts cancer-specific survival than chronological age in patients with upper tract urothelial carcinoma: a multi-institutional database study. Ther Adv Urol 10(12):403–410CrossRef
19.
Zurück zum Zitat Huang CC, Su YL, Luo HL et al (2019) Gender is a significant prognostic factor for upper tract urothelial carcinoma: a large hospital-based cancer registry study in an endemic area. Front Oncol 9:157CrossRef Huang CC, Su YL, Luo HL et al (2019) Gender is a significant prognostic factor for upper tract urothelial carcinoma: a large hospital-based cancer registry study in an endemic area. Front Oncol 9:157CrossRef
20.
Zurück zum Zitat Inamoto T, Komura K, Watsuji T, Azuma H (2012) Specific body mass index cut-off value in relation to survival of patients with upper urinary tract urothelial carcinomas. Int J Clin Oncol 17(3):256–262CrossRef Inamoto T, Komura K, Watsuji T, Azuma H (2012) Specific body mass index cut-off value in relation to survival of patients with upper urinary tract urothelial carcinomas. Int J Clin Oncol 17(3):256–262CrossRef
21.
Zurück zum Zitat Yeh HC, Jan HC, Wu WJ et al (2015) Concurrent preoperative presence of hydronephrosis and flank pain independently predicts worse outcome of upper tract urothelial carcinoma. PLoS ONE 10(10):e0139624CrossRef Yeh HC, Jan HC, Wu WJ et al (2015) Concurrent preoperative presence of hydronephrosis and flank pain independently predicts worse outcome of upper tract urothelial carcinoma. PLoS ONE 10(10):e0139624CrossRef
22.
Zurück zum Zitat Inamoto T, Matsuyama H, Ibuki N et al (2018) Biological behavior and long-term outcomes of carcinoma in situ in upper urinary tract managed by radical nephroureterectomy. J Urol 199(4):933–939CrossRef Inamoto T, Matsuyama H, Ibuki N et al (2018) Biological behavior and long-term outcomes of carcinoma in situ in upper urinary tract managed by radical nephroureterectomy. J Urol 199(4):933–939CrossRef
23.
Zurück zum Zitat Holmang S, Lele SM, Johansson SL (2007) Squamous cell carcinoma of the renal pelvis and ureter: incidence, symptoms, treatment and outcome. J Urol 178(1):51–56CrossRef Holmang S, Lele SM, Johansson SL (2007) Squamous cell carcinoma of the renal pelvis and ureter: incidence, symptoms, treatment and outcome. J Urol 178(1):51–56CrossRef
24.
Zurück zum Zitat Matin SF, Margulis V, Kamat A et al (2010) Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer 116(13):3127–3134CrossRef Matin SF, Margulis V, Kamat A et al (2010) Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer 116(13):3127–3134CrossRef
25.
Zurück zum Zitat Porten S, Siefker-Radtke AO, Xiao L et al (2014) Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer 120(12):1794–1799CrossRef Porten S, Siefker-Radtke AO, Xiao L et al (2014) Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer 120(12):1794–1799CrossRef
26.
Zurück zum Zitat Kaag MG, O'Malley RL, O'Malley P et al (2010) Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol 58(4):581–587CrossRef Kaag MG, O'Malley RL, O'Malley P et al (2010) Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol 58(4):581–587CrossRef
27.
Zurück zum Zitat Kim DK, Kim JW, Jung HD, Ahn HK, Lee JY, Cho KS (2019) Effects of adjuvant chemotherapy on locally advanced upper tract urothelial carcinoma: a systematic review and meta-analysis. Clin Genitourin Cancer Kim DK, Kim JW, Jung HD, Ahn HK, Lee JY, Cho KS (2019) Effects of adjuvant chemotherapy on locally advanced upper tract urothelial carcinoma: a systematic review and meta-analysis. Clin Genitourin Cancer
28.
Zurück zum Zitat Kondo T, Tanabe K (2012) Role of lymphadenectomy in the management of urothelial carcinoma of the bladder and the upper urinary tract. Int J Urol 19(8):710–721CrossRef Kondo T, Tanabe K (2012) Role of lymphadenectomy in the management of urothelial carcinoma of the bladder and the upper urinary tract. Int J Urol 19(8):710–721CrossRef
29.
Zurück zum Zitat Seisen T, Shariat SF, Cussenot O et al (2017) Contemporary role of lymph node dissection at the time of radical nephroureterectomy for upper tract urothelial carcinoma. World J Urol 35(4):535–548CrossRef Seisen T, Shariat SF, Cussenot O et al (2017) Contemporary role of lymph node dissection at the time of radical nephroureterectomy for upper tract urothelial carcinoma. World J Urol 35(4):535–548CrossRef
Metadaten
Titel
Adjuvant chemotherapy improves overall survival in patients with localized upper tract urothelial carcinoma harboring pathologic vascular invasion: a propensity score-matched analysis of multi-institutional cohort
verfasst von
Tomohisa Matsunaga
Kazumasa Komura
Takeshi Hashimoto
Ryu Muraoka
Naoya Satake
Takeshi Tsutsumi
Takuya Tsujino
Yuki Yoshikawa
Tomoaki Takai
Koichiro Minami
Kohei Taniguchi
Tomohito Tanaka
Hirofumi Uehara
Hajime Hirano
Hayahito Nomi
Naokazu Ibuki
Kiyoshi Takahara
Teruo Inamoto
Yoshio Ohno
Haruhito Azuma
Publikationsdatum
17.02.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 12/2020
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-020-03118-x

Weitere Artikel der Ausgabe 12/2020

World Journal of Urology 12/2020 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.